Full Report

Know the Business

Centene is the largest Medicaid managed care company in America — a $195 billion government-funded health insurance middleman that earns about 2 cents on every premium dollar in a good year and loses money in a bad one. The stock trades near book value after a brutal 2025 ($6.7 billion goodwill impairment, Medicaid cost pressures, ACA subsidy expiration), and the market is debating whether management can close a 200+ basis point gap between medical cost trends and state rate increases. The single variable that matters most: Medicaid HBR, which peaked at 94.9% in Q2 2025 and improved to 93.0% by Q4 — whether that trajectory continues into 2026 will determine if this is a turnaround or a value trap.

How This Business Actually Works

Centene collects fixed monthly premiums from governments, pays variable medical costs to providers, and keeps the spread — a model where the difference between a great year and a terrible one is 3 percentage points of margin.

States and the federal government pay Centene a per-member-per-month (PMPM) capitation rate to manage healthcare for Medicaid, Medicare, and ACA Marketplace enrollees. Centene's job is to build provider networks, manage utilization, and spend less on medical care than it collects. The economics are brutally simple:

The critical insight: a 100 basis point HBR change on $175 billion in premium revenue equals a $1.75 billion swing in profit. That single ratio explains the entire difference between FY2023 ($2.7B net income) and FY2025 (adjusted net income near $1B).

Two structural features distinguish Centene from peers. First, it deliberately does not own a PBM — unlike UnitedHealth (Optum Rx), CVS/Aetna, or Cigna (Evernorth). Management argues this lets them shop PBMs competitively against a $60 billion pharmacy spend. Second, scale primarily helps on SG&A (improved from 8.5% to 7.4% in one year) but barely moves the medical cost needle, because provider networks and utilization patterns are fundamentally local.

Revenue grew 4x from 2016 to 2024 — mostly through acquisitions (the 2020 jump is WellCare). But operating margins have oscillated between 0.9% and 3.1% with no upward trend. Scale has not translated into margin expansion. This is the central challenge of the Centene thesis.

The Playing Field

Centene is the fourth-largest US health insurer by revenue but trades at a fraction of its peers' market caps — a valuation discount that reflects structural margin inferiority, not a temporary glitch.

FY2024 financials used for margins (FY2025 distorted by impairments for CNC, HUM). Current market data for valuation. CI and UNH revenue includes large pharmacy/services businesses inflating the top line.

The most damning comparison is Molina (MOH). Molina runs essentially the same Medicaid-focused managed care business at one-quarter the scale — and generates 4.2% operating margins versus Centene's 1.9%. If scale were the advantage CNC claims, Molina should have worse margins, not better ones. Molina's edge: simpler operations, no large M&A integration overhead, and arguably better state-level execution.

UnitedHealth operates in a different league. Its 8% operating margins reflect Optum's high-margin healthcare services business, not superior insurance operations. Elevance (the former Anthem) is the more relevant benchmark for what "good" looks like in Medicaid managed care — 5% operating margins with a similar government-focused book.

The bull case for CNC requires believing that the SG&A improvements (8.5% to 7.4%) and Medicaid rate catches will eventually close the gap to Elevance-like margins. Historically, that gap has persisted.

Is This Business Cyclical?

Centene faces three overlapping cycles — medical cost, enrollment, and policy — and 2024-2025 was the rare moment when all three turned negative simultaneously.

FY2025 excluded (operating margin -3.9% distorted by $6.7B goodwill impairment). Adjusted operating margin was likely near 1-2%.

Medical cost cycle. This is what actually drives earnings. Post-COVID utilization normalization hit the entire MCO sector in 2021-2022. For Centene specifically, behavioral health — particularly Applied Behavior Analysis (ABA) therapy — drove roughly half of excess Medicaid cost trend in 2025. Management found outlier ABA providers billing 40 hours/week for 5-10 years per child (optimal is 2-3 years of balanced care). An internal task force achieved 45% reductions in outlier payment rates in one state. This is the kind of cost that states eventually address through rate adjustments and program reforms, but the lag hurts.

Enrollment cycle. Medicaid enrollment is counter-cyclical — it rises during recessions as more people qualify. But the 2023-2024 redetermination unwind (post-COVID continuous enrollment ended) shed over 2 million members. The members who left were disproportionately healthier, raising the acuity and cost of the remaining pool. This is now stabilizing: management expects 5-6% member-month attrition in 2026 from eligibility tightening and specific contract changes (Florida rolloff, New York essential plan).

Policy cycle. The Enhanced Advance Premium Tax Credits (EAPTCs) that turbocharged ACA Marketplace enrollment expired in 2025. Centene's Marketplace membership will fall from 5 million (peak) to roughly 3.5 million. Management repriced aggressively — mid-30% average rate increases for 2026 — and shifted the mix toward Bronze products (over 30% of enrollment, up from 19-24% historically). Bronze members are generally healthier and more price-sensitive, which should be margin-positive, but this is unproven at scale.

The Metrics That Actually Matter

If you understand five numbers, you understand Centene. Everything else is noise.

Medicaid HBR is the single most important number. Centene's Medicaid book is roughly $124 billion in annual premium revenue. At a 93.7% HBR, the segment is barely profitable after SG&A. Every 100 bps of HBR improvement releases approximately $1.2 billion. Getting to 91-92% — where it was in early 2024 — would add $2-3 billion in annual pre-tax earnings.

The rate-vs-trend gap is the leading indicator. In FY2025, Centene received a composite 5.5% rate increase but experienced "mid-six" medical cost trend — meaning rates were still underwater. For 2026, management expects "mid-fours" net trend, implying the gap is closing. When rate increases consistently exceed trend, margin expansion follows with a 12-18 month lag.

The market fixates on EPS guidance, but the HBR and rate gap tell you where EPS is going before management does.

What I'd Tell a Young Analyst

Watch quarterly Medicaid HBR, not annual. The Q2-to-Q4 2025 trajectory (94.9% to 93.0%) tells you more than any annual figure or EPS beat/miss. If Q1-Q2 2026 prints below 93%, the turnaround is real.

The market may be overestimating how structural CNC's margin problem is. Behavioral health costs — especially ABA therapy — are being actively reformed by states. Rate catch-ups are coming with two years of post-redetermination acuity data now in the actuarial base. Management guided conservatively ("I will be disappointed if 93.7% is all we can deliver" — CEO Sarah London, Q3 2025 call).

The market may be underestimating Marketplace risk. A 30%+ membership decline with a shift to an unproven Bronze-heavy mix is a real experiment. One bad flu season or adverse selection spiral in a lower-subsidy environment could wipe out the 4% pretax margin target.

The Magellan divestiture and $6.7 billion goodwill write-down signal management is cleaning house after an acquisition-heavy era. The question is whether this is disciplined capital allocation or a confession that the empire-building model never created value. Goodwill fell from $17.6 billion to $10.8 billion — a tacit admission that roughly 40% of acquisition value was illusory.

If you want to own managed care, the hard question is: why Centene over Molina? Molina does the same Medicaid business at higher margins with less complexity and no acquisition hangover. CNC's bull case requires believing that scale advantages will eventually materialize in margins. Nine years of data say they haven't. But the stock at book value may already reflect that pessimism — and if HBR reverts to 91-92%, adjusted EPS could significantly exceed the conservative above-$3 guidance.

Centene trades at $42 on a $195B revenue base — a 0.11x price-to-sales ratio — because the market is pricing a managed care operator whose razor-thin margins are under simultaneous pressure from Medicaid redetermination membership losses, elevated health benefits ratios (89%+), and a $6.7B goodwill impairment that signals the WellCare acquisition hasn't delivered its promised value. The single metric most likely to rerate or derate this stock is the health benefits ratio: every 100 basis points of HBR improvement on $195B of premium revenue translates to roughly $2B of operating income and $3+ per share of earnings power.

At a Glance

Centene is the third-largest managed care organization in the US by revenue, behind UnitedHealth and Cigna. It serves approximately 20 million members, primarily through Medicaid (about 64% of membership), ACA Marketplace (about 28%), and Medicare (about 5%). The stock has fallen 35% from its 52-week high of $64.15. Trailing EPS is -$13.53 due to a $6.7B goodwill impairment taken in Q3 2025; forward consensus for 2026 is $3.01 per share.

Quality Scorecard

Is this a well-run business that will still be around in 10 years?

The Altman Z-Score of 2.8 places Centene in the "grey zone" (1.8–3.0) — not in distress, but not safely above the threshold either. This is typical for large MCOs that carry significant long-term debt against thin equity bases. The Piotroski F-Score of 7/9 signals decent fundamental strength despite the FY2025 impairment year. ROE swung from a healthy 12.5% in FY2024 to -33.4% in FY2025 entirely because of the non-cash goodwill write-down, not operational collapse. Debt-to-equity rose from 2.1x to 2.9x as equity shrank by $6.5B from the impairment charge. The balance sheet is stressed but not broken — Centene ended FY2025 with $17.9B in cash against $17.5B of total debt, a near-neutral net debt position.

Revenue and Earnings Power

Revenue has grown 8.5x in a decade — from $23B in 2015 to $195B in 2025 — driven by the Health Net (2016), Fidelis Care (2018), and WellCare (2020) acquisitions. Operating income appears nearly flat on this scale because MCO margins are structurally thin: Centene earns $1–3B of operating income on $100B+ of revenue. The FY2025 plunge to -$7.6B reflects a $6.7B goodwill impairment; even excluding it, adjusted operating income was approximately -$900M, confirming genuine margin erosion in Medicaid and Marketplace.

This is the critical chart. Operating margins averaged 2.5–3.5% in the pre-WellCare era (2006–2019), compressed to under 2% post-acquisition (2021–2024), and turned deeply negative in FY2025. Each major acquisition — Health Net in 2016, Fidelis Care in 2018, WellCare in 2020 — was followed by a margin trough as integration costs and lower-margin Medicaid membership diluted profitability. The market's 64% derating from the 2018 peak of $115 directly tracks this margin erosion. Until operating margin sustainably re-crosses 2%, the stock cannot rerate.

Revenue growth accelerated sharply through 2025, reaching 20%+ YoY in Q2–Q4 despite total membership declining 7.4%. This paradox — shrinking members, surging revenue — reflects premium rate increases that more than offset membership losses. The question is whether these rate hikes keep pace with medical costs (the health benefits ratio suggests they have not).

Cash Generation — Are the Earnings Real?

Cash conversion is volatile and reveals two anomalies investors must understand. FY2024: OCF collapsed to $154M despite $3.3B of net income — a 95% cash conversion failure caused by a $7B+ working capital swing as Medicaid receivables ballooned by $4.2B and accounts payable dropped by $3.3B. This was driven by government payment timing during Medicaid redeterminations, not earnings quality. FY2025: OCF recovered to $5.1B despite a -$6.7B net loss because the goodwill impairment was entirely non-cash. Over the five-year period FY2020–2024, cumulative OCF ($24.2B) ran 2.3x cumulative net income ($10.4B) — excellent for an MCO, indicating that reported earnings understate cash generation in normal years.

Free cash flow averaged $3.9B per year over FY2021–2025 (excluding the FY2024 working capital anomaly, it averaged $5.0B). At a current market cap of $20.6B, the 5-year average FCF yield is 19% — remarkably high and suggesting either deep value or a market that expects normalized FCF to be materially lower going forward. Capex intensity is low ($0.6–1.0B per year, under 1% of revenue), typical for managed care which is an asset-light business model.

Capital Allocation

Stock-based compensation runs approximately $200M per year (under 1% of operating cash flow in normal years), which is modest for a company of this scale. Centene does not pay a regular dividend. The company conducted significant share repurchases in 2022 (financing cash outflow of $4.2B, implying roughly $3B+ in buybacks). Total shares outstanding have declined from approximately 550M to 492M over the past four years — a meaningful 11% reduction that offsets SBC dilution and then some. Capital allocation has been acquisition-heavy historically (WellCare alone cost $17.3B in 2020), but the company has shifted to debt reduction and buybacks since 2022.

Balance Sheet Health

The balance sheet tells a story of acquisition-fueled leverage followed by gradual deleveraging. Long-term debt ballooned from $1.2B (2015) to $18.6B (2021) as Centene financed the WellCare acquisition. Since then, debt has been slowly trimmed to $17.4B. The more striking development: equity dropped from $26.4B (FY2024) to $20.0B (FY2025) due to the goodwill impairment, pushing debt-to-equity from 2.1x to 2.9x. However, Centene ended FY2025 in a net cash position (-$0.3B net debt) thanks to $17.9B in cash against $17.5B in total borrowings. For a company with negative reported earnings, the liquidity position is unexpectedly strong.

Valuation — CNC vs Its Own History

The stock peaked at $115 in late 2018, just before the WellCare acquisition announcement. Since then, revenue has more than tripled from $60B to $195B, but the stock has lost 64% of its value. The market has relentlessly derated Centene as each acquisition brought in lower-margin Medicaid lives without demonstrating margin expansion. At $42, the implied price-to-sales ratio of 0.11x is the lowest in the company's publicly traded history and the lowest among large-cap managed care peers.

On FY2024 clean earnings, CNC trades at 3.3x EV/EBITDA versus a managed care industry median of 10–11x. The forward P/E of 13.9x on consensus 2026 EPS of $3.01 is roughly in line with Cigna (12x) but well below UnitedHealth (27x) and Elevance (15x). The stock currently sits 4% below the consensus analyst target of $43.47 (range: $32–$70), suggesting the market is pricing the base case with near-zero margin of safety.

Peer Comparison

CNC's P/E is not shown because trailing EPS is -$13.53 (impairment-driven); forward P/E is approximately 14x on 2026 consensus. CNC operating margin shown is FY2024 (last clean year); peers are FY2025.

The valuation gap between CNC (0.11x P/S) and UNH (0.72x P/S) is the widest in managed care and reflects a fundamental quality divide: UNH demonstrates consistent 4%+ operating margins and diversified revenue streams (Optum), while CNC has never sustained margins above 3% and is concentrated in government-sponsored programs with politically sensitive reimbursement rates. The peer most analogous to CNC is Humana — both are Medicaid/Medicare-heavy, both are struggling with elevated HBRs, and both trade at steep discounts to the diversified players. Molina, despite similar margins, commands a higher P/S due to its smaller, more focused Medicaid-only model.

Fair Value and Scenario Analysis

Bear ($28): Health benefits ratio stays above 89% through 2026, Medicaid membership declines 10%+ as redeterminations continue, 2026 EPS comes in under $2. At 12x trough earnings, the stock falls to the mid-$20s. This scenario assumes managed care repricing risk is structural, not cyclical.

Base ($45): HBR normalizes toward 88% by H2 2026, total membership decline slows to 5%, and CNC delivers approximately $3 EPS as guided. At 14–15x normalized earnings, the stock drifts toward the mid-$40s — roughly where consensus already sits. This is the "muddling through" scenario.

Bull ($75): HBR returns to 87%, Marketplace losses from 2025 are fully corrected, and operating leverage on a $195B revenue base delivers $5–6 EPS (approaching FY2024 levels). At 13–15x earnings, the stock re-rates to $65–$90. This requires margin recovery to 2%+ operating, which Centene achieved as recently as FY2024 but has not sustained post-WellCare.

The 5-year average free cash flow of $3.9B implies a 19% FCF yield at the current market cap — a valuation that either reflects deep value or a structural discount the market is unlikely to unwind until margin stability is demonstrated over multiple quarters.

---

The numbers confirm that Centene is a revenue machine generating real operating cash flow ($5B+ in normal years) at the cheapest valuation in large-cap managed care (0.11x P/S, 3.3x FY2024 EV/EBITDA), and that it ended FY2025 in a net cash position despite the impairment. The numbers contradict two popular narratives at once: the "just a one-time charge" story rings hollow because even excluding the impairment, FY2025 operating income was negative $900M — the business genuinely deteriorated; but the "CNC is broken" story also overstates the case, since operating cash flow recovered to $5.1B in FY2025 and the balance sheet is not under stress. Watch Q1 2026 earnings on April 28 and the health benefits ratio — if HBR prints under 89%, the $3/share consensus for 2026 is achievable and the stock re-rates toward $50; if it prints above 90%, the recovery thesis unravels and the bear case comes into focus.

Technical

Centene's price action is dominated by a single event: the catastrophic July 2, 2025 crash that erased 40% of the stock's value overnight on 18x normal volume. The stock has since recovered from its $25 low to $42, reclaiming both its 50-day and 200-day moving averages and printing a golden cross in late January 2026. But this recovery is rebuilding from wreckage – CNC trades 72% below its 2018 all-time high and has destroyed over a third of shareholder value over the past five years.

Price snapshot

Full-history price with 50/200 SMA

Price is above the 200-day SMA ($36.25) by 15%. This is a confirmed uptrend since early 2026, following the post-crash recovery. The secular picture, however, is a stock that ran from $17 at IPO to $149 in late 2018, then entered a multi-year downtrend with the July 2025 crash accelerating the decline. Today's price sits 72% below the all-time high.

Relative strength

CNC peaked at 146 in mid-2022 (rebased basis), then steadily eroded before the July 2025 crash sent it to 41. The partial recovery to 64 still leaves the stock down 36% over five years – a stark contrast to broad market returns.

Momentum – RSI and MACD

Near-term momentum is bullish but extended. RSI at 69.3 is one tick below overbought territory – the sharpest rally since January 2026 when RSI hit 78 before the stock pulled back from $45 to $35. The MACD histogram has been positive for three consecutive weeks and is expanding, confirming the upward thrust. The pattern to watch: after the July 2025 crash, every RSI push above 70 has been followed by a pullback of 10-15%. The current reading suggests near-term gains are likely limited before another digestion phase.

Volume and conviction

Volume has normalized since the July 2025 shock. The 50-day average has fallen from a peak of 19M shares back to roughly 6M, near pre-crash levels. The current rally is happening on average volume – not a strong conviction signal. Contrast this with the October 2025 spike (27M shares on Oct 29), which accompanied a negative price move, suggesting institutional repositioning rather than accumulation.

Volatility regime

The July 2025 crash sent 30-day realized vol to 156% – off the chart relative to the prior five-year range. It has since fallen to 39%, right at the boundary between "normal" and "stressed" (77th percentile of the 5-year distribution). The market is still pricing in more risk than usual for CNC. Pre-crash, volatility typically ranged 20-35%. The current reading suggests the name has not yet returned to a calm regime – consistent with a stock that is still finding its post-crisis equilibrium.

Technical scorecard and stance

Stance: Neutral on a 3-to-6 month horizon. The trend structure has genuinely improved – CNC is above both moving averages with a confirmed golden cross, and near-term momentum is bullish. But the recovery is fragile: volume conviction is absent, volatility remains elevated, and the five-year relative performance is deeply negative. Every RSI push above 70 since the crash has been followed by a pullback of 10-15%, and the current reading at 69 suggests the stock is approaching that ceiling again. The catalyst-driven July 2025 crash – tied to a $4B Marketplace segment headwind – fundamentally re-priced the name; whether this is a base-building phase or just a bounce within a secular downtrend depends on Centene's ability to stabilize its Marketplace segment economics. A sustained close above $45 – the January 2026 high and the zone where the golden cross initially printed – would confirm the recovery has legs. A break below $33 – the July 2025 crash floor – would signal the recovery has failed and open the door to the $25 low.

The People

Governance grade: B. A fully refreshed, independent board and a new-generation CEO executing a credible turnaround strategy, offset by negligible insider ownership and a legacy of governance scandals under prior management that required activist intervention to fix.

The People Running This Company

Centene's leadership was rebuilt from the ground up after activist Politan Capital forced a board overhaul and the exit of 25-year CEO Michael Neidorff in 2022. The current team is executing a "value over volume" strategy focused on margin recovery, portfolio simplification, and debt reduction.

London has been CEO for four years through an extremely difficult operating environment: Medicaid redeterminations, marketplace volatility, a $6.7B goodwill impairment, and a stock that fell from $64 to $25 in 2025. Her response has been disciplined: aggressive repricing, ABA fraud detection, Magellan divestiture, and SG&A cuts. She bought 19,230 shares at $25.50 in August 2025 near the 52-week low — a meaningful signal. The April 2026 executive restructure (adding Finke and Carson as group presidents) adds experienced operational depth for the next phase.

What They Get Paid

London's $20.6M total compensation is 93% equity-linked, which is structurally well-aligned. A portion of her stock options carry an exercise price of $81.85 with a performance condition requiring 20 consecutive trading days above $100 — meaning those options are currently deeply underwater at ~$42 per share. This is genuinely at-risk pay tied to shareholder outcomes.

For context, her predecessor Neidorff earned nearly $25M in 2020, making him the highest-paid healthcare executive in the US at a time when governance was deteriorating. London's pay package is comparable in size but far better structured, with most value locked in equity that only pays out if the stock recovers.

The CFO's base salary of $975K with a 100% bonus target is reasonable for a company of this scale ($175B revenue). Without the full proxy detail on Named Executive Officers, a comprehensive peer comparison is limited, but the structure is appropriate for managed care.

Are They Aligned?

Capital allocation behavior tells a more positive alignment story than raw ownership. In FY2024, management repurchased 42 million shares for $3B — a meaningful capital return when shares traded in the $60s-$70s. The 2025 pivot to debt reduction ($189M in Q4, debt-to-capital to 46.5%) and the Magellan divestiture show discipline over ego: management chose balance sheet health over headline buyback numbers when the business hit headwinds.

Smart money is loading up. David Einhorn's Greenlight Capital grew its position to 2.6M shares by Q4 2025, up 70% quarter-over-quarter. Robeco increased its stake by 427%. The institutional base sees the earnings recovery thesis.

Related-party behavior: The current board and management are clean on related-party transactions. The legacy issues — the shareholder derivative suit alleging Health Net acquisition overpayment and Neidorff-era governance — have been resolved through the board overhaul. No new related-party red flags have surfaced under current leadership.

Low ownership (0.31%) is the primary drag. Offset by CEO open-market buy at lows, deeply underwater performance options, disciplined capital allocation pivot, and clean related-party record.

Board Quality

What works: The board is genuinely refreshed — 6 of 9 directors joined in 2020-2022 as part of the Politan-driven overhaul. Chairman Eppinger is separated from the CEO, a structural improvement over the Neidorff era. The expertise mix covers insurance operations (Eppinger), audit (Blume), managed care (Burdick), CFO experience (Coughlin, Tanji), healthcare ops (Dallas), and technology (Ford). Two directors (Coughlin, Tanji) bring deep CFO-level financial oversight.

What is missing: No director has deep Medicaid policy or government affairs expertise — notable for a company whose largest segment is government-sponsored healthcare. No physician or clinical leader on the board, which is unusual for a company managing care for 28M+ members. Board gender diversity improved to 2 of 9 women (22%) but remains below best-practice targets.

Legacy governance context: This board exists because governance under Neidorff failed. Politan Capital took a $900M stake in late 2021 and forced a complete restructuring: five new directors, CEO exit, board declassification, and a Value Creation Plan. Centene also settled PBM overcharge claims with multiple states totaling over $236M (California $215M, New Hampshire $21M). The House Judiciary Committee has subpoenaed ACA insurers including Centene as part of an Obamacare subsidy fraud investigation — an ongoing regulatory risk. These are legacy issues, but they inform the governance risk premium the stock still carries.

The Verdict

What would cause an upgrade: Meaningful insider buying beyond London's single purchase — particularly from the CFO or new group presidents. Resolution of the Congressional ACA investigation without material findings. Sustained earnings recovery (the more-than-$3 EPS guide for 2026 is a start) proving the turnaround strategy works. Addition of a director with deep Medicaid/government policy experience.

What would cause a downgrade: Material adverse findings from the Congressional ACA investigation. Resumption of aggressive buybacks before the balance sheet is fully repaired. Executive departures during the critical turnaround period. New related-party or compliance issues under current management.

The Centene Story: From Acquisition Machine to Identity Crisis

Centene's five-year arc is a study in corporate reinvention gone sideways. A company that built itself through relentless M&A under founding CEO Michael Neidorff pivoted to disciplined simplification under Sarah London — only to watch its core Medicaid business buckle under post-pandemic acuity shifts, its Marketplace crown jewel absorb a morbidity shock, and its earnings collapse 71% in a single year. The question facing investors is whether the wreckage of 2025 was the clearing event that sets up durable recovery, or the first crack in a business model that government-sponsored healthcare has outgrown.

Four years of steady EPS compounding — $5.15 to $7.17 — were wiped out in a single year. The 2025 collapse was not gradual; it accelerated through the year as Medicaid acuity costs outran rate adjustments and Marketplace morbidity proved worse than actuarial models predicted. By Q4 2025, the company posted an adjusted loss of $1.19 per share in a single quarter.

Act I: The Neidorff Legacy (through 2021)

Michael Neidorff built Centene over three decades into the nation's largest Medicaid managed care organization through serial acquisitions — Health Net (2016), Fidelis Care (2018), WellCare (2020), and Magellan Health (2022). By FY2021 revenue reached $126 billion across 26.6 million members. But the acquisition machine carried costs: a bloated real estate footprint, overlapping technology platforms, and a specialty services empire (PBM, behavioral health, correctional healthcare) that distracted from core managed care operations.

Neidorff's retirement announcement in late 2021, following activist pressure, marked the end of an era. The company he built had become too complex for its own governance structure.

Act II: London's Simplification Bet (2022–2024)

Sarah London took over as CEO in March 2022 and immediately launched the Value Creation Plan — a systematic effort to shed non-core assets and refocus on government-sponsored managed care. The numbers tell the divestiture story:

Simultaneously, London drove SG&A from 9.7% of revenue in 2022 down to 7.4% by 2025 — a 230 basis point improvement representing billions in annual savings. The real estate footprint shrank 70%. A new PBM contract with ESI replaced the in-house Envolve platform. Share buybacks consumed $3 billion in 2024 alone.

Through FY2024, the strategy appeared to be working: adjusted EPS climbed from $5.78 to $7.17, the company announced a 12–15% long-term EPS growth target, and management projected "well within 5–7.5%" Marketplace pretax margins.

Act III: The 2025 Collapse

Three forces converged in 2025 to shatter the earnings trajectory:

Medicaid acuity mismatch. Redeterminations removed 2+ million lower-acuity members between 2023 and 2025, leaving a sicker remaining population. Rate adjustments lagged by 12–18 months. Q2 2025 Medicaid HBR hit 94.9% — nearly 500 basis points above the pre-redetermination baseline. London called the member shift "unprecedented" on the Q2 2024 call, insisting the mismatch was "temporary and addressable." It took two full years of rate catch-up to begin proving her right.

Marketplace morbidity surprise. The enhanced advance premium tax credits (EAPTCs) that fueled Marketplace growth from 2.1 million to 5.5 million members also attracted a sicker-than-modeled population. Wakely actuarial data confirmed the morbidity was structural, not transient. An additional $75 million medical expense provision was added in Q3 2025, on top of $200 million already reserved. Marketplace pretax margins, once targeted at 5–7.5%, collapsed.

$6.7 billion goodwill impairment. In Q3 2025, Centene wrote down $6.7 billion of goodwill — a 38% reduction — acknowledging that acquisition-era valuations no longer reflected the business reality. While non-cash, this was the most visible marker that the Neidorff-era acquisition thesis had been officially repriced.

The membership chart reveals the structural shift: Medicaid shrank from 16 million to 12.5 million members while PDP grew from 4.1 million to 8.1 million. Marketplace surged to 5.5 million before facing an expected contraction to approximately 3.5 million in 2026 as EAPTCs expire. The company that was built as a Medicaid specialist is rapidly becoming a multi-line operator where no single segment dominates.

---

What Management Emphasized — Then Stopped

The heatmap reveals three distinct narrative patterns:

Topics that vanished. "Value Creation Plan" was the organizing principle of the London era — repeated on every call from 2022 through early 2024. By FY2025 it disappeared entirely from prepared remarks. Similarly, "Acquisitions/Scale" — the vocabulary of the Neidorff era — went silent after 2022. Share buybacks, a dominant capital return narrative in FY2024 ($3 billion deployed), were barely mentioned in FY2025 as cash preservation took priority.

Topics that surged from nowhere. Behavioral health and Applied Behavior Analysis (ABA) therapy were never mentioned in earnings calls before FY2024. By FY2025, behavioral health was cited as driving "roughly half of excess trend" in Medicaid — the single largest identified cost pressure. Management launched an ABA task force, analyzed 29 states of provider data, identified 40-hour-per-week therapy patterns where 2–3 years of balanced care was the clinical standard, and filed a lawsuit against a New York provider for alleged fraud. This went from invisible to the company's most urgent operational challenge in under two years.

Topics that quietly evolved. Marketplace growth was a victory lap in FY2024 — Centene was the "undisputed leader" with 4.5 million members. By FY2025, the narrative shifted entirely to margin discipline, repricing, and managed contraction. The company filed mid-30% rate increases for 2026, deliberately reducing its low-cost silver position from 55% to 42% to prioritize profitability over market share. Bronze enrollment rose above 30% as the member mix reset toward a post-subsidy reality.

---

Risk Evolution

The risk heatmap tells a story of threats that migrated from boilerplate to boardroom:

Risks that materialized. Rate adequacy, medical cost trends, and Marketplace morbidity all escalated from low-severity boilerplate in FY2021 to critical drivers by FY2025. The company's FY2024 and FY2025 10-K filings added entirely new risk factor language around behavioral health cost acceleration, ABA therapy fraud, and the failure of actuarial models to capture post-EAPTC morbidity dynamics. These were not risks the company warned investors about early — they surfaced in filings only after the financial damage was already evident.

Risks that faded. Integration and execution risk — the dominant concern during the WellCare and Magellan absorption years of 2021–2022 — diminished as divestitures simplified the portfolio. Star ratings risk peaked in FY2024 when only 23% of MA members were in 3.5-star plans but improved materially (to 60% by late 2025).

The risk that appeared overnight. Provider fraud and abuse was effectively absent from risk disclosures through FY2023. By FY2025 it became a headline issue — Centene deployed 75 AI algorithms to score claims for fraud patterns, launched multi-state ABA provider investigations, and filed a lawsuit alleging systematic fraudulent manipulation by a New York provider. The speed of this escalation suggests the problem existed long before it appeared in risk factors.

---

How They Handled Bad News

Centene's management team showed a consistent pattern: acknowledge the problem, quantify it, then immediately redirect to the recovery narrative. This is not unusual for managed care executives, but the gap between acknowledgment and action was sometimes wide.

The most instructive example is the Medicaid acuity mismatch. In Q2 2024, London described the rate-to-acuity gap as "temporary and addressable." This proved directionally correct — rates did catch up to a 5.5% composite by 2025 — but the timeline was far longer than the word "temporary" implied. From Q2 2024 to Q4 2025, Medicaid HBR remained elevated above 93%, and the mismatch consumed six quarters of earnings before rate relief began to flow through.

On the Marketplace side, management was notably more transparent. When Wakely actuarial data confirmed the morbidity surprise in Q3 2025, the company added provisions, disclosed the external validation, and immediately began repricing for 2026 with mid-30% rate increases. There was no attempt to minimize or defer the problem.

The goodwill impairment reveals a different dimension. Writing down $6.7 billion of acquisition-era goodwill while simultaneously reporting operational distress sent a clear signal: the acquisition thesis that built Centene was being formally unwound. Management framed this as balance sheet cleanup, but it was effectively the London administration marking down the Neidorff legacy to fair value.

---

Guidance Track Record

Credibility Assessment: 45/100 — Mixed

The score reflects two sharply different data points. FY2024 guidance was conservative and well-executed: initial EPS guidance of more than $6.70 was raised to more than $6.80 and delivered at $7.17 — a meaningful beat that built investor confidence. The FY2025 guidance, however, was one of the largest misses in managed care history. Initial guidance of more than $7.25 per share was slashed to $1.75 by mid-year and eventually delivered at $2.08 — a 71% shortfall from original expectations.

The FY2025 miss was driven by factors management argues were genuinely unforeseeable: the speed of Medicaid acuity deterioration post-redetermination, the Marketplace morbidity surprise confirmed only by mid-year Wakely data, and compounding effects across both segments simultaneously. These are credible explanations, but investors must weigh them against the fact that the acuity mismatch was flagged as early as Q2 2024 — a full year before the guidance was set at $7.25.

The FY2026 guidance of more than $3.00 represents a more than 40% recovery from the trough. Management has framed it conservatively (floor, not midpoint), and the key assumptions — Medicaid rates maturing at mid-4%, Marketplace repriced at mid-30% increases, PDP growing to 8.7 million members — are individually reasonable. The question is whether they can all execute simultaneously while navigating EAPTC expiration, potential Medicaid funding cuts, and continued behavioral health cost pressure.

---

What the Story Is Now

Centene in early 2026 is a company in transition across every dimension:

Revenue is growing but earnings are not. Revenue rose from $126 billion to $195 billion over five years, but adjusted EPS ended 2025 lower than it began in 2021. Top-line growth has been driven by PDP expansion (from $4 billion to an estimated $45 billion in Medicare segment revenue), Marketplace enrollment surges, and rate increases — none of which translated to margin expansion. The company generated only $154 million in operating cash flow in FY2024, down from $8.1 billion the prior year.

The business mix is shifting rapidly. Medicaid, the founding franchise, now represents approximately $88 billion of the $172 billion premium and service revenue midpoint for 2026 — still the plurality but no longer the overwhelming majority. PDP has become the fastest-growing segment by membership, and the D-SNP (dual-eligible) alignment strategy positions Centene at the Medicaid-Medicare intersection where integrated care models carry higher per-member revenue.

The cost problem has a name. Behavioral health — specifically ABA therapy — has been identified as driving roughly half of excess Medicaid trend. This is unusual specificity for a managed care company, and it represents both a risk and an opportunity. The ABA task force, fraud detection algorithms, and multi-state provider investigations suggest management is treating this as a structural cost issue requiring multi-year intervention, not a one-time adjustment.

Legislative risk is the wild card. The OBBBA legislation introduces Medicaid work requirements (January 2027), potential per-capita cap funding, and enhanced program integrity provisions. Simultaneously, EAPTC expiration is expected to shrink Marketplace enrollment by approximately 30%. Centene faces the unusual challenge of defending two contracting government programs while trying to grow Medicare — a segment where it has yet to achieve MA breakeven.

London's bet on simplification has not failed — the SG&A gains are real, the divestitures were necessary, and the focus on core managed care is strategically sound. But the external environment has made the payoff timeline far longer and the path far more uncertain than anyone projected when the Value Creation Plan launched in 2022. The company that was "temporary and addressable" in mid-2024 is now in year two of a margin rebuild that may take until 2028 to complete.

What's Next

Centene enters its most consequential earnings cycle in years. The Q1 2026 report on April 28 — three days away — will deliver the single most important data point in this name: the first-quarter Medicaid HBR. Everything else — valuation, operating leverage, management credibility — is secondary to whether the Q4 2025 improvement was structural or seasonal. Beyond earnings, three catalysts in the next six months will shape the stock's trajectory.

The market is focused almost entirely on April 28. The consensus estimate of $2.12 EPS implies the street is pricing in modest improvement from FY2025's run rate, but the real signal is not EPS — it is the Medicaid HBR. A print below 93% would confirm that 2026 rate catch-ups are exceeding medical cost trend for the first time since redeterminations began. A print above 93.5% would suggest the Q4 2025 improvement was seasonal, putting the full-year "above $3" guidance at risk. Beyond earnings, the OBBBA work requirements effective January 2027 represent the next structural overhang — an unquantified second wave of Medicaid member attrition that neither side has fully priced.

For / Against / My View

For

Bull timeline: 12-18 months. Primary catalyst is Q1 2026 earnings on April 28 — a Medicaid HBR print below 93% confirms the recovery trajectory and forces consensus estimates higher from the $3.01 floor.

Against

Bear timeline: 12-18 months through Q3 2026 earnings. Primary trigger is Q1 or Q2 Medicaid HBR above 93%, confirming the rate catch-up narrative has stalled and the "above $3" guidance is unachievable.

The Tensions

1. Medicaid HBR at 93%: recovery confirmed or seasonal aberration?

Bull says the Q2-to-Q4 2025 trajectory (94.9% to 93.0%) is accelerating structural recovery as composite rate adjustments of 5.5% begin exceeding medical cost trend. Bear says the full-year 93.7% is still 170-270 bps above the 91-92% pre-redetermination baseline, and the Q4 improvement could reflect seasonal patterns rather than structural repricing. Both cite the same 190 bps Q2-Q4 improvement and the same 93.7% full-year figure — they disagree on whether the slope or the level tells the true story. This resolves on the Q1 2026 Medicaid HBR print on April 28 — three days from now.

2. $195B of revenue: operating leverage or structural margin drag?

Bull says every 100 bps of HBR improvement on $124B of Medicaid premiums releases approximately $1.2B in pre-tax earnings — the leverage is real and asymmetric at this scale. Bear says revenue grew 4x from $41B to $195B post-WellCare while operating margins compressed from 2.5-3.5% to under 2%, and Molina generates 4.2% operating margins at one-quarter the scale — proving the margin deficit is structural, not cyclical. Both cite the same revenue base and the same margin history; they disagree on whether scale is an asset or a liability. This resolves on whether FY2026 operating margins expand above 2% as rate catch-ups mature through H1 2026.

3. FY2024's $7.17 EPS: achievable baseline or unrepeatable peak?

Bull calls FY2024 performance "achievable margin levels, not an aberration" and builds a $68 target on recovering toward $5.00 EPS by FY2027. Bear calls the same $7.17 peak "inflated by favorable Marketplace risk adjustments and pre-redetermination Medicaid economics that are not repeatable" — a high-water mark the business will not revisit. Same number, opposite reads on whether it represents normalized earnings power or a one-time confluence. This resolves as Medicaid HBR and Marketplace margin data accumulate through H1 2026.

My View

I lean cautiously toward the bulls, but the margin of confidence is thin. The HBR trajectory from Q2 to Q4 2025 — 190 bps of improvement on a $124B premium base — is the most important data in this name, and it is moving the right direction; that is not rounding error. If Q1 prints below 93% on April 28, the operating leverage argument becomes compelling and the stock is genuinely cheap at 0.11x sales with a net cash balance sheet. But the credibility gap is severe: a management team that guided $7.25 and delivered $2.08 has not earned the benefit of the doubt, and the Marketplace repricing experiment is untested at this scale. I would wait for the April 28 print before committing — if Medicaid HBR comes in below 93%, the risk-reward tilts meaningfully bullish; if it prints above 93.5%, the recovery narrative stalls and the bear case gains weight.

Web Research

The internet reveals a deeply polarized investment story that financial filings alone cannot tell: Centene suffered a historic 40% single-day stock crash in July 2025 after withdrawing guidance due to flawed actuarial assumptions, triggering an active securities fraud class action lawsuit – yet sophisticated value investors like David Einhorn are aggressively accumulating shares, calling CNC a "coiled spring" turnaround. The web exposes a company where the bearish case (Goldman Sachs Sell rating, congressional ACA fraud investigation, $6.7B goodwill impairment) and the bullish case (deep value at 3.8x EV/EBITDA, CEO insider buying at the 52-week low, 2026 EPS guidance above consensus) are both credible, creating a binary outcome stock heading into Q1 2026 earnings on April 28.

What Matters Most

1. Historic 40% Single-Day Crash Triggered by Flawed Actuarial Assumptions (July 2, 2025)

On July 2, 2025, Centene withdrew its full-year 2025 guidance after an independent actuarial review revealed Marketplace enrollment growth was "lower than expected" and morbidity levels were "materially inconsistent with" earlier assumptions. The stock fell from $56.65 to $33.78 in a single session – a 40.4% decline wiping out more than $11 billion in shareholder value. The $1.8 billion deficit reduced EPS by $2.75/share. Jim Cramer called it "one of the most horrible stocks in the group." This was the worst single-day performance in Centene's history. (Forbes, Seeking Alpha, Investopedia)

2. Active Securities Fraud Class Action Lawsuit

Multiple law firms (Hagens Berman, Kessler Topaz, Levi and Korsinsky, Rosen Law, Faruqi and Faruqi) filed a federal securities fraud class action covering the period December 12, 2024 through June 30, 2025. Plaintiffs allege Centene and senior officers "repeatedly made false and misleading public statements" – projecting robust enrollment and favorable morbidity that were "at odds with the company's internal data." The SEC is reportedly investigating whether Centene knew about the flawed assumptions and failed to disclose the risks. As of April 2026, Bronstein Gewirtz and Grossman is still investigating. (PRNewswire, TipRanks)

3. $6.7 Billion Goodwill Impairment – Largest in Company History

In Q3 2025, Centene recorded a $6.7 billion non-cash goodwill impairment triggered by the One Big Beautiful Bill Act and the stock price decline. Combined with a $513 million Magellan Health divestiture impairment, full-year GAAP diluted loss per share was $(13.53) versus adjusted EPS of $2.08. The original 2025 EPS guidance of $7.25 was slashed to $1.75 mid-year before landing at $2.08 adjusted. Of the original $17.5B in goodwill from WellCare and other acquisitions, $10.8B remains on the balance sheet – a potential source of further impairment risk. (Investor Relations, StockTitan)

4. 2026 Turnaround Guidance: Adjusted EPS Above $3.00

On February 6, 2026, Centene guided 2026 adjusted diluted EPS above $3.00 – representing more than 40% growth over FY2025's $2.08. Reuters noted Centene was "setting itself apart from peers that have warned of persistent pressure from elevated medical costs." The guidance was above street expectations at the time, though revenue guidance of $186.5-190.5B implies a decline from 2025's $194.8B as the company sheds unprofitable Marketplace members. Management reaffirmed this guidance on March 10, 2026 and redeemed debt notes. (Reuters, TipRanks)

5. David Einhorn Aggressively Accumulating – "Coiled Spring" Thesis

Greenlight Capital's David Einhorn opened a CNC position in Q4 2024 with approximately 870K shares, growing it to over 2.6 million shares by Q4 2025 – a roughly 70% increase quarter-over-quarter. Einhorn cites a "coiled spring" thesis: Medicaid and ACA rates that lagged inflation in 2025 will realign in 2026, unlocking significant earnings power. Robeco Institutional Asset Management also increased its stake by 426.8% to 2.3 million shares (~$95M) in Q4 2025. Meanwhile, Norges Bank reduced its position by 69.5% (18.4M shares) and UBS Asset Management cut by 75.6% (14.8M shares). (Yahoo Finance, Daily Political)

6. ACA Subsidy Expiration Threatens Marketplace Business

Enhanced ACA premium tax credits (EAPTCs) have expired. According to CNBC, 9% of ACA enrollees became uninsured after enhanced subsidies ended (March 19, 2026). The Wall Street Journal reported that 1 in 7 ACA enrollees failed to make payments in 2026 (April 15, 2026). A 26-year-old enrollee reported premiums spiking $700 after subsidies ended. Centene's Marketplace membership is projected to decline from 5.5M to approximately 3.5M members, a 35% drop, with the remaining pool likely sicker and more costly. (CNBC, WSJ via TipRanks)

7. Congressional Subpoena – ACA Fraud Investigation

House Judiciary Committee Republicans have subpoenaed eight ACA health insurers, including Centene, for documents as part of an investigation into potential fraud surrounding Obamacare subsidies. This is separate from the securities fraud class action and represents an additional governance and regulatory risk. No findings or settlements have been publicly disclosed as of April 2026. (Reuters)

8. Goldman Sachs Sell Rating vs. Barclays/Bernstein Buy

Analyst sentiment is deeply divided. Goldman Sachs maintains a rare Sell rating with a price target of $32 (lowered from $38 in March 2026). In contrast, Barclays upgraded to Overweight with a $54 target in January 2026 and Bernstein rates CNC Outperform with a $59 target. The consensus is Hold (5 Buy, 13 Hold, 2-3 Sell) with a median target of $41.00. This divergence reflects fundamental disagreement about whether medical cost trends are stabilizing or structurally elevated. (Tickernerd, Yahoo Finance)

9. Medical Cost Pressure Remains Elevated

FY2025 health benefits ratio (HBR) hit 91.9%, up from 88.3% in FY2024, driven by higher Marketplace morbidity, Inflation Reduction Act PDP changes, and Medicaid behavioral health and drug costs. Q4 2025 HBR reached 94.3% (vs. 89.6% in Q4 2024). Reuters noted on February 6, 2026: "High medical costs keep Centene shares under pressure." A new headwind: hospitals are using AI-driven revenue software to aggressively trigger reimbursement claims against insurers, adding cost pressure. Management guides 2026 HBR of 90.9%-91.7%, implying improvement but still elevated versus historical norms. (Reuters, Reuters AI billing)

10. Medicaid Funding Cuts Under Trump Budget Bill

The GOP "Big Beautiful Bill" is expected to impose work requirements, stricter eligibility, and lower federal funding for Medicaid, potentially causing millions to lose coverage. Estimates suggest up to $1 trillion in Medicaid cuts. As Centene's largest segment (64% of membership), any structural reduction in Medicaid enrollment or per-member funding directly impacts revenue and margins. (CNBC, Healthcare Dive)

11. CMS Medicare Advantage 2027 Rates: Better-Than-Feared

On April 6, 2026, CMS finalized 2027 Medicare Advantage payment rates with a 2.48% average increase, described as "better-than-feared" by analysts. CNC stock jumped 5% on the news. This is a positive catalyst for Centene's Medicare strategy, particularly as the company improves Star ratings (46% of members and plans at or above 3.5 stars, up from 23%). (TipRanks, CNBC)

12. CEO Insider Buying at 52-Week Low

CEO Sarah London purchased 19,230 shares at $25.50 on August 8, 2025 – one day after CNC hit its 52-week low of $25.08. Board member Theodore Samuels also bought 9,000 shares near the trough. No material insider selling has been detected, aside from routine RSU vesting tax withholdings and Director Kenneth Burdick selling 66,007 shares over six months. The CEO's open-market purchase at the worst point in the stock's history is a meaningful alignment signal. (StockTitan SEC filings, Fintel)

Recent News Timeline

What the Specialists Asked

Insider Spotlight

CEO Sarah London purchased 19,230 shares at $25.50 on August 8, 2025, one day after the stock hit its 52-week low of $25.08. This approximately $490K open-market buy at the trough of a historic crisis is a meaningful alignment signal. She also holds 13,449 performance stock options at an $81.85 strike requiring the stock to close at or above $100 for 20 consecutive days – currently deep out-of-the-money. Total direct ownership represents 0.052% of shares outstanding, with 93.2% of her ~$20.6M total compensation tied to equity and bonuses rather than salary.

Director Kenneth Burdick is the notable seller, disposing of 66,007 shares over six months for approximately $2.58M. However, Burdick was one of the five directors installed by Politan Capital in the 2021 activism campaign, and his selling may reflect liquidity needs rather than bearish conviction.

No panic insider selling has been detected across the C-suite or board during the 2025 crisis, which is a positive governance signal given the severity of the stock decline.

The institutional ownership picture is mixed. AQR Capital added 17.1M shares (+117%) while David Einhorn's Greenlight Capital grew its position to 2.6M+ shares. On the selling side, Norges Bank removed 18.4M shares (-69.5%) and UBS Asset Management cut 14.8M shares (-75.6%). Politan Capital, the activist that drove the 2021 board overhaul, has largely exited with a 70.4% reduction. Total institutional ownership remains high at 93.63%.

Industry Context

Structural Medicaid Risk: The GOP "Big Beautiful Bill" poses the most significant long-term structural risk to Centene's dominant Medicaid franchise. Work requirements, stricter eligibility verification, and reduced federal funding could shrink the addressable Medicaid population by millions. As the nation's largest Medicaid insurer, Centene has the most absolute exposure of any managed care company.

ACA Marketplace Contraction: The expiration of enhanced advance premium tax credits is reshaping the individual insurance market. The remaining enrollment pool skews sicker and lower-income, increasing adverse selection risk. Centene is the largest Marketplace insurer through its Ambetter brand, making this a company-specific headwind more than an industry one.

Medicare Advantage Tailwind: CMS finalized 2027 Medicare Advantage rates at +2.48%, described as "better-than-feared." The Trump administration's Medicare GLP-1 drug plan is expected to cost insurers billions (Bloomberg, April 2, 2026), but the net rate environment is improving. Centene is pivoting toward higher-margin Medicare Advantage and dual-eligible (D-SNP) populations, launching an integrated model across 8 states for January 2026.

Hospital AI Billing: A new industry-wide cost pressure identified in web research: hospitals are deploying AI-driven revenue cycle software to aggressively trigger reimbursement claims against insurers (Reuters, March 12, 2026). This represents an emerging cost driver that could offset managed care companies' own AI-driven cost containment investments.

Competitive Positioning: Centene trades at a dramatic discount to managed care peers.

Centene's EV/EBITDA of 3.8x compares to an industry median of approximately 10.5x. If earnings normalize toward the $6-7 EPS range management achieved in FY2024, the stock could re-rate significantly – but that normalization is contingent on successful execution across Marketplace margin recovery, Medicaid rate catch-up, and Medicare turnaround. The Q1 2026 earnings report on April 28, 2026, is the next critical data point for validating or invalidating this thesis.